International Journal of Cancer Management

Published by: Kowsar

Circulating Levels of M30 and M65 Molecules in Transitional Cell Carcinoma of the Bladder and Their Relation to Tumor Progression

Zahra Malek-Hosseini 1 , Abdolaziz Khezri 2 and Zahra Amirghofran 3 , *
Authors Information
1 Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Department of Urology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Department of Immunology, Autoimmune Disease Research Center, Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: April 30, 2016, 9 (2); e4086
  • Published Online: April 24, 2016
  • Article Type: Research Article
  • Received: September 16, 2015
  • Accepted: March 14, 2016
  • DOI: 10.17795/ijcp-4086

How to Cite: Malek-Hosseini Z, Khezri A, Amirghofran Z. Circulating Levels of M30 and M65 Molecules in Transitional Cell Carcinoma of the Bladder and Their Relation to Tumor Progression, Int J Cancer Manag. 2016 ; 9(2):e4086. doi: 10.17795/ijcp-4086.

Copyright © 2016, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009; 27(3) : 289 -93 [DOI][PubMed]
  • 2. Shariat SF, Karam JA, Lotan Y, Karakiewizc PI. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol. 2008; 10(2) : 120 -35 [PubMed]
  • 3. Alvarez A, Lokeshwar VB. Bladder cancer biomarkers: current developments and future implementation. Curr Opin Urol. 2007; 17(5) : 341 -6 [DOI][PubMed]
  • 4. Dawam D. Biomarkers of bladder cancer in urine: evaluation of diagnostic and prognostic significance of current and potential markers. 2012;
  • 5. Weng YR, Cui Y, Fang JY. Biological functions of cytokeratin 18 in cancer. Mol Cancer Res. 2012; 10(4) : 485 -93 [DOI][PubMed]
  • 6. Karantza V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene. 2011; 30(2) : 127 -38 [DOI][PubMed]
  • 7. Ekman S, Eriksson P, Bergstrom S, Johansson P, Goike H, Gullbo J, et al. Clinical value of using serological cytokeratins as therapeutic markers in thoracic malignancies. Anticancer Res. 2007; 27(5B) : 3545 -53 [PubMed]
  • 8. Gerhard H. Cytokeratin 18 (CK18) and Caspase-Cleaved CK18 (ccCK18) as Response Markers in Anticancer Therapy.
  • 9. Linder S, Havelka AM, Ueno T, Shoshan MC. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett. 2004; 214(1) : 1 -9 [DOI][PubMed]
  • 10. Stigbrand T, Andres C, Bellanger L, Bishr Omary M, Bodenmuller H, Bonfrer H, et al. Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: the ISOBM TD5-1 Workshop. Tumour Biol. 1998; 19(2) : 132 -52 [PubMed]
  • 11. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol. 1999; 187(5) : 567 -72 [DOI][PubMed]
  • 12. Biven K, Erdal H, Hagg M, Ueno T, Zhou R, Lynch M, et al. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis. 2003; 8(3) : 263 -8 [PubMed]
  • 13. Hagg M, Biven K, Ueno T, Rydlander L, Bjorklund P, Wiman KG, et al. A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs. 2002; 20(3) : 253 -9 [PubMed]
  • 14. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res. 2004; 64(5) : 1751 -6 [PubMed]
  • 15. De Petris L, Branden E, Herrmann R, Sanchez BC, Koyi H, Linderholm B, et al. Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer. Eur J Cancer. 2011; 47(1) : 131 -7 [DOI][PubMed]
  • 16. Ausch C, Buxhofer-Ausch V, Olszewski U, Hinterberger W, Ogris E, Schiessel R, et al. Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients. Eur J Surg Oncol. 2009; 35(11) : 1164 -8 [DOI][PubMed]
  • 17. Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer. 2007; 56(3) : 399 -404 [DOI][PubMed]
  • 18. Dive C, Smith RA, Garner E, Ward T, George-Smith SS, Campbell F, et al. Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br J Cancer. 2010; 102(3) : 577 -82 [DOI][PubMed]
  • 19. Ueno T, Toi M, Biven K, Bando H, Ogawa T, Linder S. Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer. 2003; 39(6) : 769 -74 [PubMed]
  • 20. Demiray M, Ulukaya EE, Arslan M, Gokgoz S, Saraydaroglu O, Ercan I, et al. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest. 2006; 24(7) : 669 -76 [DOI][PubMed]
  • 21. Kramer G, Schwarz S, Hagg M, Havelka AM, Linder S. Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer. 2006; 94(11) : 1592 -8 [DOI][PubMed]
  • 22. Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol. 2009; 175(2) : 808 -16 [DOI][PubMed]
  • 23. de Haas EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJ, Lancashire LJ, et al. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia. 2008; 10(10) : 1041 -8 [PubMed]
  • 24. Ulukaya E, Karaagac E, Ari F, Oral AY, Adim SB, Tokullugil AH, et al. Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patients. Radiol Oncol. 2011; 45(2) : 116 -22 [DOI][PubMed]
  • 25. Bilici A, Ustaalioglu BB, Ercan S, Seker M, Yilmaz BE, Orcun A, et al. The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer. Tumour Biol. 2012; 33(6) : 2201 -8 [DOI][PubMed]
  • 26. Adlbrecht C, Hoetzenecker K, Posch M, Steiner S, Kopp C, Hacker S, et al. Elevated levels of interleukin-1beta-converting enzyme and caspase-cleaved cytokeratin-18 in acute myocardial infarction. Eur J Clin Invest. 2007; 37(5) : 372 -80 [DOI][PubMed]
  • 27. Yagmur E, Trautwein C, Leers MP, Gressner AM, Tacke F. Elevated apoptosis-associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation. Clin Biochem. 2007; 40(9-10) : 651 -5 [DOI][PubMed]
  • 28. Bantel H, Lugering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology. 2004; 40(5) : 1078 -87 [DOI][PubMed]
  • 29. Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem. 2004; 37(7) : 529 -40 [DOI][PubMed]
  • 30. Instructions for use. 2014;
  • 31. Instructions for use. 2014;
  • 32. Cummings J, Ward TH, Greystoke A, Ranson M, Dive C. Biomarker method validation in anticancer drug development. Br J Pharmacol. 2008; 153(4) : 646 -56 [DOI][PubMed]
  • 33. Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res. 2007; 13(11) : 3198 -206 [DOI][PubMed]
  • 34. Ausch C, Buxhofer-Ausch V, Olszewski U, Schiessel R, Ogris E, Hinterberger W, et al. Circulating cytokeratin 18 fragment m65-a potential marker of malignancy in colorectal cancer patients. J Gastrointest Surg. 2009; 13(11) : 2020 -6 [DOI][PubMed]
  • 35. Ramazan Sekeroglu M, Aydin S, Dulger H, Yilmaz Y, Bayrakli H, Noyan T. Diagnostic value of cytokeratin-18 as a tumor marker in bladder cancer. Clin Biochem. 2002; 35(4) : 327 -31 [PubMed]
  • 36. Song JW, Du LL, Zhao XW, Jing JX, Han CZ, Cui Y, et al. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder]. Zhonghua Zhong Liu Za Zhi. 2009; 31(4) : 274 -7 [PubMed]
  • 37. Benedict WF, Fisher M, Zhang XQ, Yang Z, Munsell MF, Dinney CN. Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNalpha/Syn3 treatment in a phase l study. Cancer Gene Ther. 2014; 21(3) : 91 -4 [DOI][PubMed]
  • 38. Koelink PJ, Lamers CB, Hommes DW, Verspaget HW. Circulating cell death products predict clinical outcome of colorectal cancer patients. BMC Cancer. 2009; 9 : 88 [DOI][PubMed]
  • 39. Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors. Int Immunopharmacol. 2009; 9(5) : 645 -8 [DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments